Related Experiment Video
Updated: Jun 27, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Integrative molecular-radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer
Ji Liu1,2, Shuwen Sun3, Yadong Guo1,2
1Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Abstract:
The efficacy of immunotherapy in bladder cancer (BCa) is highly influenced by tumor heterogeneity, underscoring the urgent need for mechanistic insights and precise molecular subtyping. Adenosine-to-inosine RNA editing (AIRE), a critical post-transcriptional mechanism driving protein diversity, offers a promising lens for decoding the immune microenvironment in BCa. In this study, we established an integrative framework combining molecular, imaging, and pathological data to identify and validate a novel immune-related BCa subtype. Based on multi-center transcriptomic datasets, we employed NMF, WGCNA, and Lasso algorithms to classify tumors into two distinct immune subtypes characterized by different levels of immune cell infiltration and divergent responses to immunotherapy. Mechanistic validation revealed that ANXA1 and RASAL2 may contribute to immunosuppressive niche formation via the TNF-NFκB-CXCL8 axis, potentially acting as molecular triggers for subtype differentiation. Furthermore, radiomic and histopathological analyses at the imaging and tissue levels supported the molecular findings, providing orthogonal validation of subtype-specific characteristics. Collectively, this study introduces an AIRE-based immune molecular subtype of BCa and systematically characterizes it across multiple dimensions. By achieving a closed-loop from identification to validation and clinical translation, our findings offer a new perspective for patients most likely to benefit from immunotherapy and advancing precision treatment strategies in bladder cancer.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Immunotherapy

